Ticker Symbol: CUR
QUEBEC CITY, March 3 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that the Company will release its first quarter 2010 results on March 17, 2010, at approximately 4:30 p.m. (EDT). This release will be followed by a conference call, which will be held on March 18, 2010, at 10:00 a.m. (EDT). The conference will begin with a brief presentation, followed by a question-and-answer period.
The event will be webcast live through DiagnoCure's website at www.diagnocure.com, through a link on the Investors page - Presentations.
For those who wish to take part in the conference call for the Q&A period, please dial the toll-free number 1-888-231-8191 and provide the subject "DiagnoCure Q1 Earnings Announcement".
For those unable to participate, a replay of the audio conference will also be available on DiagnoCure's website as of March 19, 2010, also through a link on the Investors page - Presentations.
DiagnoCure (TSX: CUR) is a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services that increase clinician and patient confidence in making critical treatment decisions. DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure Inc., launched in 2008 the Previstage(TM) GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer. A major study published in the February 18, 2009, edition of the JAMA ("Journal of the American Medical Association") demonstrated that GCC, to which DiagnoCure secured exclusive worldwide diagnostic rights, is the strongest independent predictor of colorectal cancer recurrence. The Company has a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation prostate cancer test using PCA3, DiagnoCure's proprietary molecular marker. This test is also available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA(R) PCA3 in vitro assay, and in Canada. A clinical study aimed at securing FDA approval for the commercialization of PROGENSA(R) PCA3 in the U.S. is underway. For more information, visit www.diagnocure.com.
This release contains forward-looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward-looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward-looking statements contained herein, unless required by the applicable securities laws and regulations.
SOURCE DiagnoCure Inc.
For further information: For further information: Investors: J. F. Bureau, CFA, Senior Vice President and CFO, DiagnoCure Inc., (418) 527-6100, firstname.lastname@example.org; Media: Paule De Blois, Senior Vice President, Operations, DiagnoCure Inc., (418) 527-6100, email@example.com